Baricitinib: A chance to treat COVID-19?
作者信息
Lo Caputo Sergio, Corso Gaetano, Clerici Mario, Santantonio Teresa Antonia
机构信息
Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.
Clinical Biochemistry and Clinical Molecular Biology, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.
出版信息
J Med Virol. 2020 Nov;92(11):2343-2344. doi: 10.1002/jmv.26033. Epub 2020 Jun 2.
Abstract
摘要
相似文献
1
Baricitinib: A chance to treat COVID-19?巴瑞替尼：治疗新冠病毒病的契机？
J Med Virol. 2020 Nov;92(11):2343-2344. doi: 10.1002/jmv.26033. Epub 2020 Jun 2.
2
Baricitinib Is First Approved COVID-19 Immunomodulatory Treatment.巴瑞替尼是首个获批的用于治疗新冠肺炎的免疫调节药物。
JAMA. 2022 Jun 21;327(23):2281. doi: 10.1001/jama.2022.9846.
3
An EUA for baricitinib (Olumiant) for COVID-19.巴瑞替尼（Olumiant）用于治疗新冠肺炎的紧急使用授权。
Med Lett Drugs Ther. 2020 Dec 28;62(1614):202-203.
4
Baricitinib versus tocilizumab in mechanically ventilated patients with COVID-19: a nationwide cohort study.巴瑞替尼与托珠单抗治疗新型冠状病毒肺炎机械通气患者的疗效比较：一项全国性队列研究
Crit Care. 2024 Aug 29;28(1):282. doi: 10.1186/s13054-024-05063-2.
5
Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals.在2019冠状病毒病中使用 Janus 激酶抑制剂：对522名个体的前瞻性观察系列研究
Ann Rheum Dis. 2021 Sep;80(9):1245-1246. doi: 10.1136/annrheumdis-2021-220049. Epub 2021 Jun 7.
6
Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): A systematic review and meta-analysis.巴瑞替尼治疗 2019 冠状病毒病（COVID-19）的临床疗效和不良事件：系统评价和荟萃分析。
J Med Virol. 2022 Apr;94(4):1523-1534. doi: 10.1002/jmv.27482. Epub 2021 Dec 13.
7
Successful treatment of spondyloenchondrodysplasia with baricitinib.巴瑞替尼成功治疗脊椎骨骺发育不良
Rheumatology (Oxford). 2021 Feb 1;60(2):e44-e46. doi: 10.1093/rheumatology/keaa356.
8
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.巴瑞替尼治疗住院 COVID-19 成人患者的疗效和安全性（COV-BARRIER）：一项随机、双盲、平行分组、安慰剂对照的 3 期临床试验。
Lancet Respir Med. 2021 Dec;9(12):1407-1418. doi: 10.1016/S2213-2600(21)00331-3. Epub 2021 Sep 1.
9
Audio Interview: Covid-19 Vaccine Fundamentals.音频访谈：新冠疫苗基础知识
N Engl J Med. 2020 Dec 17;383(25):e146. doi: 10.1056/NEJMe2035370.
10
Inhibition of Progression of Acrodermatitis Continua of Hallopeau With Baricitinib.巴瑞替尼抑制Hallopeau连续性肢端皮炎的进展
JAMA Dermatol. 2021 Apr 1;157(4):466-468. doi: 10.1001/jamadermatol.2021.0045.
引用本文的文献
1
Recent progress in discovery of novel AAK1 inhibitors: from pain therapy to potential anti-viral agents.新型 AAK1 抑制剂的研究进展：从疼痛治疗到潜在的抗病毒药物。
J Enzyme Inhib Med Chem. 2023 Dec;38(1):2279906. doi: 10.1080/14756366.2023.2279906. Epub 2023 Nov 13.
2
Roles of existing drug and drug targets for COVID-19 management.现有药物及药物靶点在新冠肺炎治疗中的作用。
Metabol Open. 2021 Sep;11:100103. doi: 10.1016/j.metop.2021.100103. Epub 2021 Jun 29.
3
The Janus Kinase Inhibitor Ruxolitinib Prevents Terminal Shock in a Mouse Model of Arenavirus Hemorrhagic Fever.Janus激酶抑制剂芦可替尼可预防沙粒病毒出血热小鼠模型中的终末期休克。
Microorganisms. 2021 Mar 9;9(3):564. doi: 10.3390/microorganisms9030564.
4
Inflammation, immunity and potential target therapy of SARS-COV-2: A total scale analysis review.SARS-COV-2 的炎症、免疫及潜在靶点治疗：全尺度分析综述。
Food Chem Toxicol. 2021 Apr;150:112087. doi: 10.1016/j.fct.2021.112087. Epub 2021 Feb 25.
5
Variants in ACE2; potential influences on virus infection and COVID-19 severity.ACE2 基因变异；对病毒感染和 COVID-19 严重程度的潜在影响。
Infect Genet Evol. 2021 Jun;90:104773. doi: 10.1016/j.meegid.2021.104773. Epub 2021 Feb 17.
6
Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?衰老、免疫与2019冠状病毒病：年龄如何影响宿主对冠状病毒感染的免疫反应？
Front Physiol. 2021 Jan 12;11:571416. doi: 10.3389/fphys.2020.571416. eCollection 2020.
7
COVID-19: Characteristics and Therapeutics.新型冠状病毒肺炎（COVID-19）：特征与治疗。
Cells. 2021 Jan 21;10(2):206. doi: 10.3390/cells10020206.
8
Understanding COVID-19 Pandemic: Molecular Mechanisms and Potential Therapeutic Strategies. An Evidence-Based Review.理解新冠疫情：分子机制与潜在治疗策略。一项基于证据的综述。
J Inflamm Res. 2021 Jan 7;14:13-56. doi: 10.2147/JIR.S282213. eCollection 2021.
9
JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.JAK 抑制可降低 SARS-CoV-2 的肝脏感染性，并调节炎症反应，从而降低发病率和死亡率。
Sci Adv. 2021 Jan 1;7(1). doi: 10.1126/sciadv.abe4724. Print 2021 Jan.
10
Drug repurposing and cytokine management in response to COVID-19: A review.药物再利用和细胞因子管理以应对 COVID-19：综述。
Int Immunopharmacol. 2020 Nov;88:106947. doi: 10.1016/j.intimp.2020.106947. Epub 2020 Aug 31.
本文引用的文献
1
COVID-19: combining antiviral and anti-inflammatory treatments.2019冠状病毒病：联合抗病毒与抗炎治疗
Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27.
2
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.巴瑞替尼作为2019新型冠状病毒急性呼吸道疾病的潜在治疗方法。
Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4.
3
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
Zotero 插件